In an interview with Psychiatric Times, Arthur Caye, MD, PhD, highlighted his innovative research in addressing a persistent challenge in psychiatry—the limited utility of biomarkers in differentiating between clinical cases and controls. The poster by Caye et al, "Enhanced Neurobiological Biomarker Differentiation for Attention-Deficit/Hyperactivity Disorder through a Risk-Informed Case-Control Design," was presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology.